Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

**Botulinum Toxin**

**MB9020**

**Covered Service:**
Yes—when meets criteria below and is a covered benefit of the member’s plan.

**Prior Authorization Required:**
Yes—as shown below

**Additional Information:**
Please note the types of Botulinum Toxin are listed separately below

**Medicare Policy:**
Dean Health Plan covers when Medicare also covers the benefit.

**BadgerCare Plus Policy:**
Dean Health Plan covers when BadgerCare Plus also covers the benefit.

**Dean Health Plan Approved Criteria:**

OnabotulinumtoxinA, IncobotulinumtoxinA, RimabotulinumtoxinB and AbobotulinumtoxinA requires prior authorization through the Quality and Care Management Division and is considered medically necessary for members who meet the following criteria for the listed indications. **All other diagnoses are considered experimental and investigational and may not be approvable.**

**IncobotulinumtoxinA (XEOMIN) (J0588)** may be indicated for the following:

1.0 Cervical dystonia (spasmodic torticollis) in patients 16 years of age or older when all of the following criteria are met:
   1.1 No infection at proposed injection site; and
   1.2 Neck pain or abnormal head position causing adverse effect on daily functioning; and
   1.3 No fixed contractures causing decreased neck range of motion; and
   1.4 No neuromuscular disease (eg, myasthenia gravis).

2.0 Blepharospasm for patients age 18 or older, as indicated by ALL of the following:
   2.1 Diagnosis of benign essential blepharospasm
   2.2 No neuromuscular disease
   2.3 No infection at proposed injection site

3.0 Upper Limb Spasticity in adults due to stroke
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

**RimabotulinumtoxinB (MYOBLOC) (J0587)** may be indicated for the following:

4.0 Cervical dystonia (spasmodic torticollis) in patients 16 years of age or older when all of the following criteria are met:
   4.1 No infection at proposed injection site; and
   4.2 Neck pain or abnormal head position causing adverse effect on daily functioning; and
   4.3 No fixed contractures causing decreased neck range of motion; and
   4.4 No neuromuscular disease (eg, myasthenia gravis).

5.0 Sialorrhea (excessive salivation) due to neurologic disease

**AbobotulinumtoxinA (DYSPORT) (J0586)** may be indicated for the following:

6.0 Blepharospasm for patients age 18 or older, as indicated by ALL of the following:
   6.1 Diagnosis of benign essential blepharospasm
   6.2 No neuromuscular disease
   6.3 No infection at proposed injection site

7.0 Cervical dystonia (spasmodic torticollis) in patients 16 years of age or older when all of the following criteria are met:
   7.1 No prior surgical treatment; and
   7.2 No infection at proposed injection site; and
   7.3 Neck pain or abnormal head position causing adverse effect on daily functioning; and
   7.4 No fixed contractures causing decreased neck range of motion; and
   7.5 No neuromuscular disease (eg, myasthenia gravis).

8.0 Hemifacial spasm

9.0 Hyperhidrosis (axillary) in patients 18 years of age or older when all of the following criteria are met:
   9.1 Significant effect of hyperhidrosis on daily activities; and
   9.2 Conservative treatment, including topical agents, have failed; and
   9.3 Secondary causes of hyperhidrosis (eg, hyperthyroidism) have been evaluated and, if necessary, treated.
   9.4 No infection at proposed injection site.
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

9.5 Axillary hyperhidrosis, with resting sweat production of 50 mg per axilla measured over 5 minutes at room temperature.

10.0 Sialorrhea (excessive salivation)

11.0 Spasticity, as indicated by 1 or more of the following:
   11.1 Child with cerebral palsy receiving rehabilitation; or
   11.2 Upper extremity spasticity in adult due to stroke

12.0 Upper extremity dystonia (eg, writer's cramp), for patient's age 16 years or older, as indicated by ALL of the following:
   12.1 Extremity pain or abnormal hand or forearm position causing adverse effect on daily functioning; and
   12.2 No prior surgical treatment; and
   12.3 No infection at proposed injection site

OnabotulinumtoxinA (BOTOX) (J0585) may be indicated for one (1) or more of the following:

13.0 Achalasia when all of the following criteria are met:
   13.1 Progressive dysphagia for liquids and solids; and
   13.2 Diagnosis of achalasia confirmed by esophageal manometry; and
   13.3 Other causes of dysphagia ruled out by upper gastrointestinal endoscopy; and
   13.4 Pharmacological treatment has failed.

14.0 Anal fissure when all of the following criteria are met:
   14.1 At least 2 months of symptoms including one of the following: nocturnal pain and bleeding OR post-defecation pain; and
   14.2 No inflammatory bowel disease; and
   14.3 No hemorrhoids; and
   14.4 No HIV disease; and
   14.5 No anal fistula; and
   14.6 No perianal abscess, cancer or previous surgery; and
   14.7 Failure or intolerance of topical nitrates; and
   14.8 Patient is not a surgical candidate
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

15.0  Blepharospasm in patients 12 years of age or older who have blepharospasm associated with no neuromuscular disease (e.g., myasthenia gravis) and at least one of the following:

15.1 Dystonia; or
15.2 Facial nerve disorders (e.g., Bell Palsy); or
15.3 Benign essential blepharospasm.

16.0  Cervical dystonia (spasmodic torticollis) in patients 16 years of age or older when all of the following criteria are met:

16.1 No infection at proposed injection site; and
16.2 Neck pain or abnormal head position causing adverse effect on daily functioning; and
16.3 No fixed contractures causing decreased neck range of motion; and
16.4 No neuromuscular disease (e.g., myasthenia gravis).

17.0  Hemifacial spasm

18.0  Hyperhidrosis (axillary) in patients 18 years of age or older when all of the following criteria are met:

18.1 Significant effect of hyperhidrosis on daily activities; and
18.2 Conservative treatment, including topical agents, have failed; and
18.3 Secondary causes of hyperhidrosis (e.g., hyperthyroidism) have been evaluated and, if necessary, treated.
18.4 No infection at proposed injection site.
18.5 Axillary hyperhidrosis, with resting sweat production of 50 mg per axilla measured over 5 minutes at room temperature.

19.0  Migraine headache prophylaxis needed for those 18 years or older, as indicated by all of the following:

19.1 Migraine headache, as indicated by 5 or more attacks with ALL of the following:

19.1.1 Headache symptoms, as indicated by 2 or more of the following:

19.1.1.1 Aggravation by or causing avoidance of routine physical activity
19.1.1.2 Moderate or severe pain intensity
19.1.1.3 Pulsating quality
19.1.1.4 Unilateral location

19.2 Migraine associated symptoms, as indicated by either nausea/vomiting, or Photophobia and phonophobia.
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

19.3 Migraine headache frequency occurring 15 or more days per month for 3 or more months

19.4 No medication-overuse headaches

19.5 No neuromuscular disease (e.g., myasthenia gravis)

19.6 Other therapeutic options have been ineffective or not tolerated for trial of at least 3 months, as indicated by 1 or more of the following:
   19.6.1 Use of ergotamine, triptans, or combination analgesics for 10 or more days per month or
   19.6.2 Use of simple analgesics or any combination of ergotamine, triptans, analgesics, and opioids for 15 or more days per month

19.7 Have tried and failed trials of at least 3 medications selected from at least two classes of migraine headache prophylaxis medications of at least 2 months duration for each medication:
   19.7.1 Beta blockers (e.g., propranolol, atenolol)
   19.7.2 Anti-depressants (e.g., amitriptyline)
   19.7.3 Anti-epileptics (e.g., gabapentin, topiramate)
   19.7.4 Calcium channel blockers (e.g., verapamil)
   19.7.5 Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., Lisinopril, losartan)

19.8 Continuing treatment with botulinum toxin injection for ongoing prevention of chronic migraine headaches is considered medically necessary when there is documentation that migraine headache frequency was reduced or duration was reduced.

20.0 Motor tics in patients 16 years of age or older when all of the following criteria are met:
   20.1 The tics cause interference with daily living; and
   20.2 Patient unable to adequately suppress tics; and
   20.3 Failure of trials of several different neuroleptic drugs (e.g., haloperidol).

21.0 Neurogenic urinary incontinence, neurogenic detrusor overactivity or detrusor sphincter dyssynergia when all of the following criteria are met:
   21.1 The condition is secondary to a spinal cord injury or neurologic disease (e.g., multiple sclerosis); and
   21.2 Surgical treatment or balloon sphincter dilatation is not indicated or has failed; and
   21.3 Pharmacologic therapy has failed: and
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

21.4 No acute urinary retention unless patient receiving regular clean intermittent catheterization; and

21.5 Age 18 years or older.

22.0 Overactive bladder with urge urinary incontinence, as indicated by all of the following:

22.1 Age 18 years or older; and

22.2 Failure of or intolerance to anticholinergic medication; and

22.3 No acute urinary retention; and

22.4 No acute urinary tract infection; and

22.5 Urge urinary incontinence demonstrated on urodynamic testing

23.0 Sialorrhea (excessive salivation)

24.0 Spasticity, as indicated by 1 or more of the following:

24.1 Child with cerebral palsy receiving rehabilitation; or

24.2 Hereditary spastic paraplegia; or

24.3 Limb spasticity due to multiple sclerosis or other demylenating diseases of the central nervous system

24.4 Spastic hemiplegia, such as due to stroke or brain injury

25.0 Strabismus in patients 12 years of age or older when all of the following criteria are met:

25.1 Deviation of 50 prism diopters or less; and

25.2 No infection at proposed injection site; and

25.3 Strabismus not due primarily to restrictive strabismus, Duane syndrome with lateral rectus weakness, or caused by prior surgical over-recession of antagonist muscle.

26.0 Upper extremity dystonia (eg, writer's cramp), for patient's age 16 years or older, as indicated by all of the following:

26.1 Extremity pain or abnormal hand or forearm position causing adverse effect on daily functioning; and

26.2 No prior surgical treatment; and

26.3 No infection at proposed injection site
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

<table>
<thead>
<tr>
<th>Committee/Source</th>
<th>Date(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Originated:</td>
<td></td>
</tr>
<tr>
<td>Utilization Management Committee/Blue Cross/Blue Shield, Technologica, 9/96, The Executive Summary File, Vol. 11, No. 6, 1996</td>
<td>February 19, 1997</td>
</tr>
<tr>
<td>Revised:</td>
<td></td>
</tr>
<tr>
<td>Utilization Management Committee/ Medical Affairs Technology Review</td>
<td>September 9, 1999</td>
</tr>
<tr>
<td>Utilization Management Committee/ Dean GI Dept.</td>
<td>January 19, 2000</td>
</tr>
<tr>
<td>Utilization Management Committee/ Customer Service</td>
<td>February 14, 2001</td>
</tr>
<tr>
<td>Utilization Management Committee/ Medical Affairs/ Medicare Part B, 3/2002</td>
<td>October 10, 2001</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>May 8, 2002</td>
</tr>
<tr>
<td>Medical Director Committee/ Referral Dept.</td>
<td>July 10, 2002</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>February 11, 2004</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>January 14, 2009</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>June 10, 2009</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>June 16, 2010</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>November 18, 2010</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>June 23, 2011</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>September 19, 2012</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>March 19, 2014</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>August 20, 2014</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>January 21, 2015</td>
</tr>
<tr>
<td>Medical Director Committee/ Medical Affairs</td>
<td>May 20, 2015</td>
</tr>
<tr>
<td>Medical Director Committee/ Quality and Care Management Division</td>
<td>December 16, 2015</td>
</tr>
<tr>
<td>Medical Policy Committee/ Quality and Care Management Division</td>
<td>May 18, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/ Quality and Care Management Division</td>
<td>September 21, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/ Quality and Care Management Division/ Pharmacy Services</td>
<td>August 16, 2017</td>
</tr>
<tr>
<td>Reviewed:</td>
<td></td>
</tr>
<tr>
<td>Health Services</td>
<td></td>
</tr>
<tr>
<td>Managed Care Division/ Medical Affairs Department</td>
<td>February 17, 1999</td>
</tr>
<tr>
<td>Managed Care Division / Medical Affairs Department</td>
<td>March 20, 2000</td>
</tr>
<tr>
<td>Utilization Management Committee/ CMO/ Director UM</td>
<td>April 11, 2001</td>
</tr>
<tr>
<td>UM</td>
<td>March 13, 2002</td>
</tr>
<tr>
<td>UM Committee (UMC)/ Director UM/ UMC Chair</td>
<td>March 12, 2003</td>
</tr>
<tr>
<td>Utilization Management Committee/ Medical Affairs/ Medicare Part B, 11/2003</td>
<td>January 14, 2004</td>
</tr>
<tr>
<td>UM Committee (UMC)/ Director UM/ UMC Chair</td>
<td>March 10, 2004</td>
</tr>
</tbody>
</table>
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

<table>
<thead>
<tr>
<th>Committee/Source</th>
<th>Date(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reviewed:</td>
<td></td>
</tr>
<tr>
<td>Utilization Management Committee/ Medical Affairs/ Medicare Part B, 12/2004</td>
<td>January 12, 2005</td>
</tr>
<tr>
<td>UM Committee (UMC)/Director UM/ UMC Chair</td>
<td>March 9, 2005</td>
</tr>
<tr>
<td>Utilization Management Committee/Medical Affairs/ Medicare Part B, 3/2005</td>
<td>April 13, 2005</td>
</tr>
<tr>
<td>Utilization Management Committee/Medical Affairs/ HAYES, Inc. 11/2005</td>
<td>January 11, 2006</td>
</tr>
<tr>
<td>Reformatted</td>
<td>January 2006</td>
</tr>
<tr>
<td>Utilization Management Committee/Medical Affairs</td>
<td>January 10, 2007</td>
</tr>
<tr>
<td>Utilization Management Committee/Medical Affairs</td>
<td>February 14, 2007</td>
</tr>
<tr>
<td>UM Committee (UMC)/Director UM/UMC Chair</td>
<td>March 14, 2007</td>
</tr>
<tr>
<td>UM Committee (UMC)/Director UM/UMC Chair</td>
<td>March 12, 2008</td>
</tr>
<tr>
<td>UM Committee (UMC)/Director UM/UMC Chair</td>
<td>April 8, 2009</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>June 16, 2010</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>June 23, 2011</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>June 20, 2012</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>August 15, 2012</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>September 19, 2012</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>January 16, 2013</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>January 15, 2014</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>March 19, 2014</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>August 20, 2014</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>January 21, 2015</td>
</tr>
<tr>
<td>Medical Director Committee/Medical Affairs</td>
<td>May 20, 2015</td>
</tr>
<tr>
<td>Medical Director Committee/Quality and Care Management Division</td>
<td>December 16, 2015</td>
</tr>
<tr>
<td>Medical Director Committee/Quality and Care Management Division</td>
<td>January 20, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td>May 18, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td>September 21, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td>August 16, 2017</td>
</tr>
</tbody>
</table>

Effective 09/01/2017
Published: 09/01/2017